HAYLEY'S COMET II

COMETE DE HAYLEY II

English Abstract

A new cultivar of medical cannabis has been bred that renders relatively large

amounts of cannabidiolic acid (mg/gram ground flower weight)...greater than
10%.
The cultivar moved from an outdoor to indoor environment produced similar
levels
of cannabidiolic acid (CBD-A) and similar cannabinoid profiles. Reproduced
asexually, the same (greater than 10%) cannabidiolic acid amounts were
rendered
and this remains constant crop to crop. THC levels do not change between 20
and
30% of that of the CBD-A concentration. High Pressure Liquid Chromatography
(HPLC) determines cannabinoid profiles where the amounts of the three most
abundant cannabinoids (tetrahydrocannabinol, cannabinol, and cannabidiol) and
their acids are quantified. The cannabinoid profile relates directly to the
physiological effects of the plant as a medicine. In addition, a genetic
fingerprint of
the strain has been generated using gel electrophoresis. Strains high in
cannabidiolic acid are rare since breeding has favored the high THC strains
for their
psychoactive effects (recreational cannabis). Hayley's Comet II provides a
unique
cannabinoid profile containing large concentrations of CBA-A making it useful
for
medicaments for seizure disorder, pain and inflammation.

Claims

Claims:
Claim 1: A method whereby a unique cannabinoid profile as determined by High
Pressure Liquid Chromatography (HPLC), defines a specific cultivar of
asexually
reproducing cannabis.
Claim 2: A method whereby a genetic profile (fingerprint), defines a specific
cultivar
of asexually reproducing cannabis.
Claim 3: A method whereby a cannabidiolic acid concentration of greater than
100
mg/gram (of ground flower weight), is consistently found in the specific
cultivar.
Claim 4: A method whereby a tetrahydrocannabinol concentration of less than
15%
(of ground flower weight), is consistently found in the specific cultivar of
asexually
reproducing cannabis.
Claim 5: A method whereby the DNA profile at locus Cind 16FR (bp) differs from

other comparable strains and having a distinct fragment pattern characteristic
of
the cultivar.
Claim 6: A method whereby the DNA profile at locus Cind1FR differs from other
comparable strains and having a distinct fragment pattern characteristic of
the
cultivar.
Claim 7: A method whereby the DNA profile at locus Cind5 differs from other
comparable strains and having a distinct fragment pattern characteristic of
the
cultivar.
Claim 8: A method whereby the DNA profile at locus Cind24FR differs from other

comparable strains and having a distinct fragment pattern characteristic of
the
cultivar.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid
profile useful in the treatment of epilepsy, chronic pain and imflammation.

Description

Background of the Invention:
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention

described here refers to natural cannabidiolic acid compounds and their
decarboxylated derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than
95%,
that can be used in medical studies, whereas the invention described here is a

means of obtaining cannabidiolic acid in its natural form, plus inclusion of
the other
natural cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form, the invention
described here addresses cannabidiolic acid in its natural form and means of
obtaining CBD-A.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and
cannabidiol
using super critical fluid extraction whereas the invention described here
employs
not extraction of compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as
antagonists
to the CB1 and CB2 receptors, whereas the invention described here is merely a

continues source of cannabidiolic acid and other carboxylated cannabinoids.

A strain of cannabis with high concentrations of cannabidiolic acid was bred,
whereby with asexual reproduction cannabidiolic acid concentrations (as
determined by HPLC) remains consistent and the genetic fingerprint remains
inimitable within cannabis subspecies. The DNA profile was generated using gel

electrophoresis and compared to a number of common strains of similar type.
The unique DNA fingerprint plus the cannabinoid profile characterize the
strain,
plus morphological description, cloning, growth and pest resistance add to
distinguishing this plant form others of its type.

CA 02859934 2014-08-18
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with
unique
cannabinoid and DNA profiles, represented by high cannabidiolic acid to
tetrahydrocannabinolic acid ratios.
2.) A further objective of the inventions is to preserve a strain of cannabis
with
high ratios of CBD-A to THC-A to be used in medicaments.
3.) A further objective of the invention is to propagate the strain for yields
of
CBD-A
4.) A further objective of the invention is to propagate the strain for use in

medicaments for chronic pain and seizure disorder.
5.) A further objective of the invention is to propagate a strain with
consistent
cannabinoid profiles of high CBD-A to THC-A ratios.
6.) A further objective of the invention is to use this strain to breed other
strains
with a similar high CBD-A to THC-A ratio.
Summary of the Invention
A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid
profile
with greater than 100 mg/gram (of ground, dried, flower weight) CBD-A is
consistently produced and the THC concentration consistently less than 150
mg/gram, of ground flower weight.